Klerk Mariska, Verhoef Petra, Clarke Robert, Blom Henk J, Kok Frans J, Schouten Evert G
Division of Human Nutrition and Epidemiology, Wageningen University, PO Box 8129, 6700 EV Wageningen, The Netherlands.
JAMA. 2002;288(16):2023-31. doi: 10.1001/jama.288.16.2023.
In observational studies, individuals with elevated levels of plasma homocysteine tend to have moderately increased risk of coronary heart disease (CHD). The MTHFR 677C-->T polymorphism is a genetic alteration in an enzyme involved in folate metabolism that causes elevated homocysteine concentrations, but its relevance to risk of CHD is uncertain.
To assess the relation of MTHFR 677C-->T polymorphism and risk of CHD by conducting a meta-analysis of individual participant data from all case-control observational studies with data on this polymorphism and risk of CHD.
Studies were identified by searches of the electronic literature (MEDLINE and Current Contents) for relevant reports published before June 2001 (using the search terms MTHFR and coronary heart disease), hand searches of reference lists of original studies and review articles (including meta-analyses) on this topic, and contact with investigators in the field.
Studies were included if they had data on the MTHFR 677C-->T genotype and a case-control design (retrospective or nested case-control) and involved CHD as an end point. Data were obtained from 40 (34 published and 6 unpublished) observational studies involving a total of 11 162 cases and 12 758 controls.
Data were collected on MTHFR 677C-->T genotype, case-control status, and plasma levels of homocysteine, folate, and other cardiovascular risk factors. Data were checked for consistency with the published article or with information provided by the investigators and converted into a standard format for incorporation into a central database. Combined odds ratios (ORs) for the association between the MTHFR 677C-->T polymorphism and CHD were assessed by logistic regression.
Individuals with the MTHFR 677 TT genotype had a 16% (OR, 1.16; 95% confidence interval [CI], 1.05-1.28) higher odds of CHD compared with individuals with the CC genotype. There was significant heterogeneity between the results obtained in European populations (OR, 1.14; 95% CI, 1.01-1.28) compared with North American populations (OR, 0.87; 95% CI, 0.73-1.05), which might largely be explained by interaction between the MTHFR 677C-->T polymorphism and folate status.
Individuals with the MTHFR 677 TT genotype had a significantly higher risk of CHD, particularly in the setting of low folate status. These results support the hypothesis that impaired folate metabolism, resulting in high homocysteine levels, is causally related to increased risk of CHD.
在观察性研究中,血浆同型半胱氨酸水平升高的个体患冠心病(CHD)的风险往往会适度增加。亚甲基四氢叶酸还原酶(MTHFR)677C→T多态性是参与叶酸代谢的一种酶的基因改变,会导致同型半胱氨酸浓度升高,但其与冠心病风险的相关性尚不确定。
通过对所有有此多态性和冠心病风险数据的病例对照观察性研究的个体参与者数据进行荟萃分析,评估MTHFR 677C→T多态性与冠心病风险的关系。
通过检索电子文献(MEDLINE和《现刊目次》)查找2001年6月之前发表的相关报告(使用检索词MTHFR和冠心病),人工检索关于该主题的原始研究和综述文章(包括荟萃分析)的参考文献列表,并与该领域的研究人员联系来确定研究。
如果研究有MTHFR 677C→T基因型数据且为病例对照设计(回顾性或巢式病例对照),并以冠心病作为终点,则纳入研究。数据来自40项(34项已发表和6项未发表)观察性研究,共涉及11162例病例和12758例对照。
收集关于MTHFR 677C→T基因型、病例对照状态以及同型半胱氨酸、叶酸和其他心血管危险因素的血浆水平的数据。检查数据与已发表文章或研究人员提供的信息是否一致,并转换为标准格式以纳入中央数据库。通过逻辑回归评估MTHFR 677C→T多态性与冠心病之间关联的合并比值比(OR)。
与CC基因型个体相比,MTHFR 677 TT基因型个体患冠心病的几率高16%(OR,1.16;95%置信区间[CI],1.05 - 1.28)。与北美人群(OR,0.87;95% CI,0.73 - 1.05)相比,欧洲人群的结果存在显著异质性(OR,1.14;95% CI,1.01 - 1.28),这在很大程度上可能由MTHFR 677C→T多态性与叶酸状态之间的相互作用来解释。
MTHFR 677 TT基因型个体患冠心病的风险显著更高,尤其是在叶酸水平低的情况下。这些结果支持这样的假设,即叶酸代谢受损导致高同型半胱氨酸水平,与冠心病风险增加存在因果关系。